A clinical trial to study the neurocognitive effects of tdcs in patients with schizophrenia
Not Applicable
- Conditions
- Health Condition 1: null- patients with schizophrenia
- Registration Number
- CTRI/2018/04/013039
- Lead Sponsor
- Kasturba medical college
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients diagnosed with schizophrenia (F20) according to ICD-10 Diagnostic Criteria for Research (DCR)
2. Age between: 18 and 60 of either sex
3. Patients who are on same psychotropic medication for at least 3 months
4. No ECTs in the last six months.
5. Patients who consent to participate (Informed consent)
6. 6 years of formal education
Exclusion Criteria
1. Comorbid major psychiatric disorders, substance dependence excluding tobacco use
2. Chronic major medical or neurological disorders
3. Subjects with skeletal deformities of scalp
4. Metallic implants
5. Change in medication in the last 3 months.
6. Eligibility criteria for the control group will be the same
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MCCB (MATRICS Consensus Cognitive Battery) ,the mean changes of the changes across the domains of the battery will be assessedTimepoint: a baseline assessment of MCCB will be done 1 day prior to the recruitment and then assessments will be done again one hour after 10th session of tdcs and after one month after the tdcs procedure
- Secondary Outcome Measures
Name Time Method PANSS: Positive and Negative Syndrome Scale for Schizophrenia <br/ ><br>CGI: Clinical Global Impression <br/ ><br>SCoRS: Schizophrenia Cognition Rating Scale <br/ ><br>TDCS adverse effect questionnaire <br/ ><br>Timepoint: before the interventions is started and then after tenth session of tdcs and after 1 month